Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.

byBenzinga Newsdesk

January 24, 2023

1 minute read

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.

What’s Going On With NIO Shares On Friday?

By Nabaparna Bhattacharya

May 24, 10:43 AM

NIO shares are marginally down. The company plans to hold an annual general meeting and release its first-quarter results, while the company's expansion efforts in Europe continue to draw attention.

NIO

Analyst Ratings

Analyst Ratings for ADC Therapeutics

By Benzinga Insights

November 9, 10:24 AM

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

ADCT

Chinese Exporters Grapple With Challenges Despite China’s Economic Growth: ‘We’re Selling Electrical Appliances As Cheap As Cabbage’

By Benzinga Neuro

April 17, 8:58 AM

Exporters are currently facing increased economic and political tensions with the United States, a global trade slowdown due to the Ukraine conflict, and a deepening crisis in the Middle East.

MCHI